Conference Coverage
Conference Coverage
Study supports add-on therapy for germline and wildtype BRCA mutations
The findings put to rest the notion that patients with germline BRCA mutations would not benefit from carboplatin treatment because of sensitivity...
Conference Coverage
Most community-based oncologists skip biomarker testing
Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.
Conference Coverage
Twelve-month overall survival benefit with ribociclib for metastatic breast cancer
It’s the first phase 3 trial to report a median overall survival beyond 5 years in advanced breast cancer.
Conference Coverage
DCIS: Biosignature helps guide postlumpectomy decisions
The tool shows promise for identifying those whose cancer is likely to recur despite undergoing postlumpectomy radiotherapy.
Conference Coverage
Promising HER2+/HR– breast cancer survival with de-escalated therapy
Conference Coverage
Pilot study: Hybrid laser found effective for treating genitourinary syndrome of menopause
Further studies are important to improve the understanding of "laser dosimetry, frequency of treatments, and longevity of effect.
Conference Coverage
CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancer
Conference Coverage
Genomic signature predicts safety of omitting RT in early breast cancer
Conference Coverage
ACE inhibitor prevents trastuzumab-associated LVEF decline after anthracyclines in BC treatment
Conference Coverage
Pregnancy effect on chemotherapy does not affect maternal breast cancer outcomes